ProQR Therapeutics N.V.

ProQR's revenue is forecast to grow at 49% per year, significantly outpacing the broader U.S. market at 13% annually. Evercore ISI raised its price target to $6 with an Outperform rating, reflecting strong confidence in the company's pipeline and its ability to generate meaningful top-line growth from upcoming clinical catalysts.

Despite revenue growth projections, ProQR is forecast to remain unprofitable over the next three years, with deeply negative net margins of 331.33% and a negative return on equity of 84.87%. The company posted quarterly revenue of $2.35 million — less than half of analyst estimates of $5.19 million — highlighting a persistent gap between expectations and execution.

The consensus among eight covering analysts is a 'Buy,' with an average price target of $8.25 — representing upside of over 385% from recent trading levels. Oppenheimer resumed coverage with an Outperform rating and a $9 target, while Cantor Fitzgerald maintained an Overweight rating with an $8 target, signaling broad institutional conviction in significant undervaluation.

Despite the optimistic consensus, Chardan Research cut its price target from $4 to $3, and JonesTrading reduced its target from $11 to $10. Weiss Ratings downgraded PRQR to a 'sell (e+)' rating, and Wall Street Zen issued a 'strong sell,' underscoring deep skepticism about whether lofty price targets are grounded in near-term financial reality.

CEO Daniel Anton de Boer purchased 150,000 shares at market, a notable insider buy that signals strong management confidence in the company's trajectory. With shares trading around $1.73 — well below the consensus analyst target of $7.33 — this insider activity suggests leadership believes the stock is meaningfully undervalued relative to its pipeline prospects.

ProQR priced a $50 million underwritten direct offering of over 27.6 million shares at $1.81 per share, representing significant dilution for existing shareholders. The concurrent share offering prospectus filing for an additional 3.03 million shares further raises concerns about the company's reliance on repeated equity raises to fund operations, pressuring the stock price.